Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron achieves strong sales growth for travellers’ diarrhoea product

The company sold $335,000 worth of Travelan in the U.S. market during H1 FY2018.
Travelan product
The company's share price has increased circa 34% in 2018

Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) flag-ship product Travelan® has achieved a revenue in excess of $914,000 for the first six months of FY2018, experiencing strong sales growth in both the U.S. and Australia.

Travelan is a natural product, specifically designed to reduce the risk of infection by E.coli, the most common cause of travellers’ diarrhoea or Bali Belly.

The company sold $335,000 worth of Travelan in the U.S. market during H1 FY2018, representing a 250% increase on the same period last year.

Travelan had $579,000 in sales in the Australian market, representing a 27% increase on the same period last year.

New clinical study of IMM-529

Immuron is also developing and commercializing other oral immunetherapeutics for the treatment of gut related diseases.

Last month, the company enrolled the first patients into its first-in-human IMM-529 clinical study for the treatment of clostridium difficile infection (CDI).

Most commonly affecting older adults after use of antibiotic medications, CDI can cause symptoms that range from diarrhea to life-threatening gut inflammation.

IMM-529 uses a combination of polyclonal antibodies to target and neutralise the three main virulence factors of CDI without negatively impacting the microbiome.

Clostridium-difficile infection is a multi-billion dollar market

According to the Centers for Disease Control and Prevention (CDC), clostridium-difficile infects more than 450,000 patients causing over 29,000 deaths per year in the U.S alone.

There is a high likelihood for recurrence of symptoms, which nearly triples the healthcare costs per patient, resulting in annual healthcare costs of nearly $4.5 billion.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017

Related Articles

car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use